<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Precision oncology advancements &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/precision-oncology-advancements/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 20 Oct 2025 15:33:35 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Precision oncology advancements &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Precision Reprogramming: How AI Outsmarts Cancer’s Most Resilient Cells</title>
		<link>https://bioengineer.org/precision-reprogramming-how-ai-outsmarts-cancers-most-resilient-cells/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 20 Oct 2025 15:33:04 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI-driven cancer therapy]]></category>
		<category><![CDATA[Cancer stem cell reprogramming]]></category>
		<category><![CDATA[Colon cancer treatment innovation]]></category>
		<category><![CDATA[Machine learning in cancer research]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<guid isPermaLink="false">https://bioengineer.org/precision-reprogramming-how-ai-outsmarts-cancers-most-resilient-cells/</guid>

					<description><![CDATA[In a groundbreaking advancement poised to reshape cancer therapy, scientists at the University of California San Diego have devised a novel method to obliterate cancer stem cells—those notoriously elusive agents driving tumor recurrence, metastasis, and resistance to treatment. Distinct from conventional approaches that often harm healthy tissue, this innovative strategy selectively reprograms cancer stem cells, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">283840</post-id>	</item>
		<item>
		<title>Promising New Drug Combo Provides Hope for Men with Advanced Prostate Cancer</title>
		<link>https://bioengineer.org/promising-new-drug-combo-provides-hope-for-men-with-advanced-prostate-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 07 Oct 2025 09:14:33 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[HRR gene mutations]]></category>
		<category><![CDATA[metastatic castration-sensitive prostate cancer]]></category>
		<category><![CDATA[PARP inhibitor combination therapy]]></category>
		<category><![CDATA[phase III clinical trial]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<guid isPermaLink="false">https://bioengineer.org/promising-new-drug-combo-provides-hope-for-men-with-advanced-prostate-cancer/</guid>

					<description><![CDATA[A groundbreaking international clinical trial, spearheaded by researchers at University College London (UCL), has uncovered a promising therapeutic advancement for men afflicted with a particularly aggressive form of prostate cancer. This new treatment strategy combines niraparib, a PARP inhibitor, with the standard hormone therapies abiraterone acetate and prednisone, offering hope for significantly delayed disease progression [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">276796</post-id>	</item>
		<item>
		<title>New Insights into Immunotherapy Failure Offer New Hope for Cancer Patients</title>
		<link>https://bioengineer.org/new-insights-into-immunotherapy-failure-offer-new-hope-for-cancer-patients/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 17 Sep 2025 18:15:50 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[bexmarilimab cancer therapy]]></category>
		<category><![CDATA[immunotherapy resistance mechanisms]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<category><![CDATA[secreted Clever-1 protein]]></category>
		<category><![CDATA[T cell activation suppression]]></category>
		<guid isPermaLink="false">https://bioengineer.org/new-insights-into-immunotherapy-failure-offer-new-hope-for-cancer-patients/</guid>

					<description><![CDATA[A groundbreaking study led by researchers at the University of Birmingham, in collaboration with the University of Turku in Finland, has unveiled a pivotal mechanism behind the failure of immunotherapy in numerous cancer patients. Supported by the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre, this investigation sheds light on a [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">269989</post-id>	</item>
		<item>
		<title>Harnessing Deep Learning to Revolutionize Precision Cancer Therapy</title>
		<link>https://bioengineer.org/harnessing-deep-learning-to-revolutionize-precision-cancer-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 15 Sep 2025 08:59:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AI-driven cancer treatment solutions]]></category>
		<category><![CDATA[computational biology in cancer therapy]]></category>
		<category><![CDATA[Flexynesis deep learning toolkit]]></category>
		<category><![CDATA[multi-omics data integration]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<guid isPermaLink="false">https://bioengineer.org/harnessing-deep-learning-to-revolutionize-precision-cancer-therapy/</guid>

					<description><![CDATA[In a groundbreaking advance that promises to transform the landscape of precision oncology, Altuna Akalin and his research team at the Max Delbrück Center for Molecular Medicine have unveiled Flexynesis, an innovative deep learning toolkit designed to integrate and analyze complex multi-omics data alongside diverse clinical information. Published in the prestigious journal Nature Communications, this [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">269087</post-id>	</item>
		<item>
		<title>Antibody–Bottlebrush Prodrugs Revolutionize Targeted Cancer Therapy</title>
		<link>https://bioengineer.org/antibody-bottlebrush-prodrugs-revolutionize-targeted-cancer-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 09 Sep 2025 11:32:46 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[antibody-bottlebrush prodrugs]]></category>
		<category><![CDATA[drug-to-antibody ratio optimization]]></category>
		<category><![CDATA[payload diversity in cancer treatments]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<category><![CDATA[targeted cancer therapy innovations]]></category>
		<guid isPermaLink="false">https://bioengineer.org/antibody-bottlebrush-prodrugs-revolutionize-targeted-cancer-therapy/</guid>

					<description><![CDATA[In the relentless pursuit of advanced cancer therapeutics, antibody–drug conjugates (ADCs) have carved a significant niche due to their ability to selectively deliver potent cytotoxic agents directly to tumor cells. Despite their clinical success, conventional ADCs face notable challenges that hinder their broader application. Primarily, these challenges include limitations in incorporating less-potent payloads, constraints in [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">267866</post-id>	</item>
		<item>
		<title>City of Hope Receives $23.7 Million Grant to Map Biomarkers of Treatment Resistance in Common Lung Cancer</title>
		<link>https://bioengineer.org/city-of-hope-receives-23-7-million-grant-to-map-biomarkers-of-treatment-resistance-in-common-lung-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 18 Jun 2025 04:31:02 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[ARPA-H funded cancer research]]></category>
		<category><![CDATA[Biomarker mapping for cancer treatment]]></category>
		<category><![CDATA[Dynamic tumor evolution analysis]]></category>
		<category><![CDATA[Immunotherapy resistance in NSCLC]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<guid isPermaLink="false">https://bioengineer.org/city-of-hope-receives-23-7-million-grant-to-map-biomarkers-of-treatment-resistance-in-common-lung-cancer/</guid>

					<description><![CDATA[City of Hope Secures Landmark $23.7 Million Grant to Revolutionize Immunotherapy Resistance in Non-Small Cell Lung Cancer In a groundbreaking advancement for cancer research, City of Hope, one of America’s premier cancer centers, has been awarded a contract valued at up to $23.7 million by the Advanced Research Projects Agency for Health (ARPA-H), part of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">249711</post-id>	</item>
		<item>
		<title>DiosMetin Targets INF2: New Colorectal Therapy</title>
		<link>https://bioengineer.org/diosmetin-targets-inf2-new-colorectal-therapy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 02 Jun 2025 07:48:53 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Colorectal cancer therapy]]></category>
		<category><![CDATA[DiosMetin 7-O-β-D-Glucuronide]]></category>
		<category><![CDATA[INF2 biomarker]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<category><![CDATA[single-cell RNA sequencing]]></category>
		<guid isPermaLink="false">https://bioengineer.org/diosmetin-targets-inf2-new-colorectal-therapy/</guid>

					<description><![CDATA[Colorectal cancer (CRC) remains one of the most formidable challenges in oncology, ranking as the third most prevalent malignancy within the gastrointestinal tract and occupying the position of the second leading cause of cancer-related mortality worldwide. For decades, researchers have pursued the identification of molecular targets that could enable the development of efficacious, precision therapies. [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">247853</post-id>	</item>
		<item>
		<title>Tailored Treatment Using Combined Tissue and Liquid Biopsies Enhances Patient Outcomes Compared to Individual Approaches</title>
		<link>https://bioengineer.org/tailored-treatment-using-combined-tissue-and-liquid-biopsies-enhances-patient-outcomes-compared-to-individual-approaches/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 29 Apr 2025 13:14:00 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[combined tissue and liquid biopsies]]></category>
		<category><![CDATA[genomic profiling concordance]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<category><![CDATA[survival outcomes in advanced cancer]]></category>
		<category><![CDATA[tumor heterogeneity detection]]></category>
		<guid isPermaLink="false">https://bioengineer.org/tailored-treatment-using-combined-tissue-and-liquid-biopsies-enhances-patient-outcomes-compared-to-individual-approaches/</guid>

					<description><![CDATA[Patients battling advanced solid tumors have shown notably improved survival rates when their treatment was guided by genomic alterations identified in both tissue and liquid biopsies, reveals compelling new data from the phase II ROME trial. Presented at the prestigious American Association for Cancer Research (AACR) Annual Meeting 2025, these findings illuminate the critical role [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">242546</post-id>	</item>
		<item>
		<title>Revolutionizing Breast Cancer Treatment: The Role of Liquid Biopsy</title>
		<link>https://bioengineer.org/revolutionizing-breast-cancer-treatment-the-role-of-liquid-biopsy/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 18 Feb 2025 18:15:06 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[circulating tumor DNA testing]]></category>
		<category><![CDATA[genetic mutations in breast cancer]]></category>
		<category><![CDATA[Liquid biopsy technology]]></category>
		<category><![CDATA[Non-invasive cancer diagnostics]]></category>
		<category><![CDATA[Precision oncology advancements]]></category>
		<guid isPermaLink="false">https://bioengineer.org/revolutionizing-breast-cancer-treatment-the-role-of-liquid-biopsy/</guid>

					<description><![CDATA[A groundbreaking study on circulating tumor DNA (ctDNA) testing for patients suffering from advanced breast cancer has emerged, yielding significant findings that may transform the landscape of oncology treatment. This research underscores the pivotal role of ctDNA as a non-invasive means to detect genetic mutations that can influence treatment decisions, thereby enhancing the precision of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">236334</post-id>	</item>
	</channel>
</rss>
